Skip to content

May 7, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
M&A / Deals
Angelini inks $4.1B Catalyst buy to enter US rare disease market

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

BioSpace

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Read full story

pharminent May 7, 2026 (Last updated: May 7, 2026)

BioSpace

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Read full story

Post navigation

Previous: Bayer plans filings for cardiac amyloidosis imaging agent

Next: FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

Related Stories

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

M&A / Deals

Daiichi Sankyo and Waiv partner for ADC biomarkers

pharminent May 7, 2026

M&A / Deals

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

pharminent May 6, 2026

You May Have Missed

Regulatory

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

pharminent May 7, 2026

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

pharminent May 7, 2026

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.